Reposted by Sean Langenfeld

Among persons with residual invasive disease after treatment of HER2-positive early breast cancer, trastuzumab emtansine resulted in 7-year invasive disease–free survival of 80.8%, as compared with 67.1% with trastuzumab. Full KATHERINE study results: nej.md/3WhKMJN
#MedSky #Oncology